MedTrace Logo

High Altitude (HA) Residents With Pulmonary Vascular Diseases (PVD), 6 Minute Walk Distance (6MWD) Assessed at 2840m (HA) With and Without Supplemental Oxygen Therapy (SOT)

NCT06003244 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-10-05

No results posted yet for this study

Summary

The investigators aim to study the effect of SOT in participants with pulmonary vascular diseases (PVD) defined as pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension (PH) who permanently live \>2500m on 6-minute walk distance (6MWD) assessed at 2840m.

Conditions

  • Pulmonary Vascular Disease
  • Pulmonary Artery Hypertension
  • Chronic Thromboembolic Pulmonary Hypertension

Interventions

OTHER

6-minute walk distance (6MWD) test

6-minute walk distance (6MWD) test will be performed according to clinical standards

OTHER

6-minute walk distance (6MWD) test with supplemental oxygen (3 l/min, nasal)

6-minute walk distance (6MWD) test will be performed according to clinical standards additionally with supplemental oxygen therapy (3l/min, nasal)

Sponsors & Collaborators

  • University of Zurich

    lead OTHER

Principal Investigators

  • Silvia Ulrich, Prof. Dr. · University Hospital Zurich, Departement of Pulmonology

  • Rodrigo Hoyos, Dr. · Carlos Adrade Marin Hospital of Quito, Equador

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-23
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06003244 on ClinicalTrials.gov